Treatment Guidelines for Medical Providers

Hidradenitis Suppurativa is a chronic, debilitating, inflammatory disease, which affects up to 1% of the U.S. population. The following guidelines are based on current evidence and practice trends, emphasizing the role of dermatologists in treatment recommendations.


Access the full hidradenitis suppurativa guideline from JAAD (free):


Publications on HS

Find Hidradenitis Suppurativa publications in the National Library of Medicine.


Downloads

Facts about Hidradenitis Suppurativa (HS) Pamphlet:

HS Pamphlet Download


Prior Authorization Templates:

HS Prior Authorization Template: Adalimumab
 
HS Prior Authorization Template: Anakinra
 
HS Prior Authorization Template: Apremilast

HS Prior Authorization Template: brodalumab
 
HS Prior Authorization Template: Certolizumab pegol
 
HS Prior Authorization Template: Ertapenem
 
HS Prior Authorization Template: Guselkumab

HS Prior Authorization Template: Infliximab 
 
HS Prior Authorization Template: Laser Hair Removal
 
HS Prior Authorization Template: onabotulinumtoxinA (Botox)

HS Prior Authorization Template: Risankizumab
 
HS Prior Authorization Template: Secukinumab
 
HS Prior Authorization Template: Tofacitinib
 
HS Prior Authorization Template: Ustekinumab